PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))

About this update from Pharmather Holdings Ltd

Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio Chianelli, the Company's Founder, Chairman and Chief Executive Officer, has issued the following letter to shareholders. Dear Fellow Shareholders, Earlier this year, I wrote to you about the challenges we faced with our FDA Priority Original Abbreviated New Drug Application for our ketamine product, which we have named KETARx™. I was thrilled to receive the FDA approval letter on Friday, August 8, 2025, for KETARx™, for its use in surgical pain management (anesthesia and sedation). We proudly announced this milestone on Monday, August 11, 2025. This approval is more than just an achievement—it is a turning point. Our journey has been long, filled with determination, resilience, and belief in ketamine's transformative potential. Now, we have not just seen the light at the end of the tunnel—we've stepped into it. With this success, a new era begins for PharmaTher, and I believe the opportunities ahead could be game-changing for PharmaTher, our shareholders, and most importantly, the millions of patients in need. The Road Ahead - From Approval to Impact We are moving swiftly into pre-launch commercialization of KETARx™ in the U.S. while also preparing international regulatory filings. Bringing a drug to market requires handling of many moving parts—marketing, sales, manufacturing, and global cost-optimization strategies, just to name a few. While this complexity is expected, the immediate surge of interest from specialty pharmaceutical companies—ranging from large to mid-sized industry players to niche innovators—has been nothing short of exhilarating. Partnership discussions are already underway, but make no mistake—we are also advancing our commercial plan to launch KETARx™ this year. We have a clear and scalable sales channel targeting hospitals, specialty clinics, government institutions such as the U.S. Department of Defense and Veterans Health Administration, as well as clinical research programs and support for special or expanded access programs. And this is only Phase One. Millions of surgical patients stand to benefit today, but the long-term potential for ...

View stock analysis, news, and events for Pharmather Holdings Ltd